STAT+: Three biotechs with three news updates

Gilead wins case over its HIV medicine, Eli Lilly to expand retatrutide access, and more biotech news Darron Cummings/AP Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I’ve decided to paint the walls in one of my rooms a dark brown. I may deeply regret this decision. Please send any painting tips! The need-to-know this morning Earnings: Vertex, Pfizer, and Merck. Lilly will review applications for special access to experimental drug Over a month ago, STAT reported that Eli Lilly had granted a single 79-year-old patient special access to its next-gen obesity drug retatrutide. Now, the pharma company says it will allow other patients to apply for early access to the therapy as well. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.